Category Archives: Patent Term Extension

Letter: Over 30 civil society organisations urge EU to abolish supplementary protection certificates mechanism

Source: MSF Access Campaign In an open letter and open submission, thirty-three civil society organisations have called on the European Commission to abolish the supplementary protection certificates (SPC) mechanism and to stop encouraging the inclusion of SPCs – or similar mechanisms, such … Continue reading

Posted in Patent Term Extension, Uncategorized | Leave a comment

NGOs call for supplementary protection certificates to be abolished

By Carmen Paun 9/11/17, 1:43 PM CET A group of 33 civil society organizations led by Doctors Without Borders today asked the European Commission to abolish supplementary protection certificates (SPCs), which they claim lead to unaffordable medicines prices that stay in place for … Continue reading

Posted in Patent Term Extension, Uncategorized | Leave a comment

Indian patent office delivers major blow to affordable pneumonia vaccine hopes

MSF Access Campaign August 22, 2017   Geneva/New York/New Delhi, 22 August 2017 – Hopes for improved access to an affordable pneumococcal conjugate vaccine (PCV) that safeguards both children and adults from pneumonia was dealt a major blow after the Indian … Continue reading

Posted in Indian Patent Law, Indian Patent Office, Patent, Patent Opposition, Patent Term Extension, Uncategorized, Vaccines | Tagged , | Leave a comment

What’s at stake in Hyderabad

By Feroz Ali, The Hindu | July 28, 2017 India must counter Japan’s U.S.-style pressure at the RCEP talks and ensure affordable generic medicines Leaked texts are like leaked gases — you may never find the one responsible for it, … Continue reading

Posted in Data Exclusivity, IP Rights, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized | Leave a comment

No logic in extending length of patents

Granting a longer term for pharmaceutical patents will result in delays in the entry of generic versions and could adversely affect access to medicines   By Feroz Ali, Live Mint | July 28, 2017 A proposal to further extend the … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Trading away health

By Rohit Malpani, The Hindu | July 23, 2017 Hyderabad, well known as the hub of the Indian pharmaceuticals industry, ranks third globally in terms of its production volume, with a turnover of Rs. 18 billion a year. Most of … Continue reading

Posted in Data Exclusivity, FTA, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized | Leave a comment

Regional Comprehensive Economic Partnership: Boosting trade or extending monopolies for big pharma?

Published: The Huffington Post India By Leena Menghaney, Head—South Asia, Médecins Sans Frontières (MSF) Access Campaign. MÉDECINS SANS FRONTIÈRES (MSF) Officials from the 16 countries negotiating the Regional Comprehensive Economic Partnership (RCEP) trade deal—which includes the ten ASEAN member states, … Continue reading

Posted in Data Exclusivity, FTA, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized | Leave a comment